Eur Rev Med Pharmacol Sci 2019; 23 (4): 1434-1442

DOI: 10.26355/eurrev_201902_17100

MicroRNA-29b sensitizes osteosarcoma cells to doxorubicin by targeting matrix metalloproteinase 9 (MMP-9) in osteosarcoma

D.-J. Luo, L.-J. Li, H.-F. Huo, X.-Q. Liu, H.-W. Cui, D.-M. Jiang

Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. dianm_jiang@163.com


OBJECTIVE: To discover the effect and mechanism of exogenous microRNA-29b (miR-29b) on proliferation, apoptosis and the sensitivity to chemotherapy of osteosarcoma (OS) cells.

PATIENTS AND METHODS: We assessed the expression of microRNA-29b in osteosarcoma tissues evaluating the regulation of in on the OS cell growth and drug sensitivity in human osteosarcoma MG-63 cell model. Firstly, quantitative RT-PCR (reverse transcription-PCR, RT-PCR) was used to measure the expression of miR-29b and matrix metallopeptidase 9(MMP-9) in primary osteosarcoma samples, and to evaluate the correlation between the two molecules. Secondly, miR-29b mimics or mimics were used to modify its expression in MG-63 cells. Luciferase reporter assay, Western blotting, cell viability, colony forming assay and apoptosis examination were performed to assess the regulation by manipulated miR-29b in the osteosarcoma-derived cells.

RESULTS: We found that miR-29b is down-expressed, whereas the MMP-9 level was markedly higher in primary osteosarcoma tissues and osteosarcoma-derived cells. We also found that exogenous miR-29b reduces the proliferation, promotes the apoptosis and upregulates the sensitivity to chemotherapy (doxorubicin) of osteosarcoma cells via direct targeting of the MMP-9.

CONCLUSIONS: Our data suggest that the reduced miRNA-29b may serve as a predictor of response to chemotherapy and as a therapeutic target in human osteosarcomas.

Free PDF Download

To cite this article

D.-J. Luo, L.-J. Li, H.-F. Huo, X.-Q. Liu, H.-W. Cui, D.-M. Jiang
MicroRNA-29b sensitizes osteosarcoma cells to doxorubicin by targeting matrix metalloproteinase 9 (MMP-9) in osteosarcoma

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 4
Pages: 1434-1442
DOI: 10.26355/eurrev_201902_17100